This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up (before enrollment) and each follow-up point, all clinical indicators of patients were recorded to measure the therapeutic effect.

开始日期2023-01-01

申办/合作机构

李氏大药厂控股有限公司

NCT05293704 / Not yet recruiting临床4期

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

This study is divided into two parts: ① Part I was a retrospective observational study. Kidney transplant recipients infected with BK virus (BKV) in the First Affiliated Hospital of Sun Yat-sen University from 2015 to 2021 were retrospectively collected and divided into case group and control group whether to convert MPA drug to mizoribine. ② The second part was a prospective, open and interventional clinical trial. Thirty patients with positive urinary BK virus after kidney transplantation using Mycophenolic acid (MPA) were enrolled in the First Affiliated Hospital of Sun Yat-sen University. All patients who met the inclusion criteria were treated with mizoribine to place MPA (Mycophenolate or mycophenolate sodium enteric coated tablets) for 12 months as directed. At the baseline of follow-up (before enrollment) and at each follow-up point, clinical indicators of patients were recorded, and renal biopsy was performed to evaluate the occurrence of BKV nephropathy in patients with persistent elevated BK viruria or persistent BK viremia after conversion and patients with BK viruria after 12 months, and to judge the progress after early activation of BKV and the safety of mizoribine.

开始日期2022-05-01

申办/合作机构

李氏大药厂控股有限公司

JPRN-jRCTs051200070 / Completed临床2期

Efficacy of mizoribine after two years of cyclosporine treatment for children with frequently relapsing nephrotic syndrome

开始日期2020-12-23

申办/合作机构-

100 项与咪唑立宾相关的临床结果

登录后查看更多信息

100 项与咪唑立宾相关的转化医学

登录后查看更多信息

100 项与咪唑立宾相关的专利（医药）

登录后查看更多信息

692

项与咪唑立宾相关的文献（医药）

2024-03-29·Current Topics in Medicinal Chemistry

Approaches Towards Better Immunosuppressive Agents

Article

作者: Walczak, Juliusz ; Iwaszkiewicz-Grześ, Dorota ; Cholewiński, Grzegorz

Abstract:Several classes of compounds are applied in clinics due to their immunosuppressive properties in transplantology and the treatment of autoimmune diseases. Derivatives of mycophe-nolic acid, corticosteroids and chemotherapeutics bearing heterocyclic moieties like methotrexate, azathioprine, mizoribine, and ruxolitinib are active substances with investigated mechanisms of action. However, improved synthetic approaches of known drugs and novel derivatives are still being reported to attempt better accessibility and therapeutic properties. In this review article, we present the synthesis of the designed chemical structures based on recent literature reports con-cerning novel compounds as promising immunosuppressive drugs. Moreover, some of the dis-cussed derivers revealed also other types of activities with prospective medicinal potential.

2023-12-01·Gan to kagaku ryoho. Cancer & chemotherapy

[A Case Report of the Ascending Colon Cancer with Bullous Pemphigoid].

Review

作者: Imamura, Hiroshi ; Yanagimoto, Yoshitomo ; Dono, Keizo ; Shimizu, Junzo ; Iijima, Ken ; Kawase, Tomono ; Yamashita, Masafumi ; Tomita, Naohiro ; Ikenaga, Masakazu ; Takeyama, Hiroshi ; Odagiri, Kazuki ; Suzuki, Yozo

The patient was a 70-year-old man. The patient had progressive anemia while taking 10 mg/day of prednisolone and 100 mg/day of mizoribine orally for bullous pemphigoid, a colonoscopy diagnosed ascending colon cancer. Adenocarcinoma, Group 5 was detected on biopsy. Abdominal computed tomography showed no metastases. The tumor was diagnosed as ascending colon cancer, cT4aN0M0, cStage Ⅱb. We performed laparoscopic right hemicolectomy and D3 dissection. Histopathological examination revealed pT3N0M0, pStage Ⅱa. In the present report, we describe a case of the ascending colon cancer with bullous pemphigoid, and discuss the case with a review of the literature.

2023-12-01·Pediatric Nephrology

Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis

Article

作者: Yoshikawa, Norishige ; Sakakibara, Nana ; Ishimori, Shingo ; Fujimura, Junya ; Ninchoji, Takeshi ; Ichikawa, Yuta ; Iijima, Kazumoto ; Ueda, Chika ; Horinouchi, Tomoko ; Tanaka, Yu ; Kamiyoshi, Naohiro ; Tanaka, Ryojiro ; Kaito, Hiroshi ; Kitakado, Hideaki ; Nagai, Sadayuki ; Nakanishi, Koichi ; Nozu, Kandai ; Aoto, Yuya ; Kondo, Atsushi ; Shima, Yuko

BACKGROUNDPatients with severe IgA vasculitis with nephritis (IgAVN) typically receive aggressive therapy as an initial approach. We have consistently performed combination therapy including corticosteroids and immunosuppressants as initial therapy for severe IgAVN over a 20-year-plus period, with only minor changes to the treatment protocol. This study seeks to reveal the efficacy of combination therapy for severe IgAVN.METHODSWe retrospectively studied 50 Japanese children diagnosed between 1996 and 2019 with clinicopathologically severe IgAVN who were defined as ISKDC classification grade IIIb-V and/or serum albumin < 2.5 g/dL.RESULTSThe median age at the onset of IgAVN was 8.0 years (IQR: 6.0-10.0). At biopsy, 44% of patients had nephrotic syndrome and 14% had kidney dysfunction. All patients were treated with combination therapy after biopsy. Abnormal proteinuria resolved after initial therapy in all 50 patients. However, eight patients (16%) had recurrence of proteinuria. Abnormal proteinuria was again resolved in three of these patients with additional treatment. At the last follow-up (median 59.5 months; IQR, 26.2-84.2), the median urine protein-to-creatine ratio was 0.08 g/gCr (IQR, 0.05-0.15), and only one patient had kidney dysfunction.CONCLUSIONSCombination therapy provided good kidney outcomes for Japanese children with severe IgAVN. Even including recurrent cases, the degree of proteinuria was slight, and kidney function was good at the last follow-up. A higher resolution version of the Graphical abstract is available as Supplementary information.

项与咪唑立宾相关的新闻（医药）

2023-07-17

·信狐药迅

GSK 长效HIV药卡替拉韦获批进口，普拉格雷、艾曲泊帕多个仿制不批准 | 新获批（7.10-7.16）

每周药品注册受理数据，分门别类呈现，一目了然。（7.10-7.16）新药上市申请无新药临床申请药品名称企业名称分类受理号BPYT-01胶囊百极优棠(广东)医药科技有限公司1CXHL23004471CXHL2300449CF04滴眼液上海普佑生物医药有限公司1CXSL23002671CXSL23002681CXSL23002691CXSL2300270FCN-437c胶囊锦州奥鸿药业有限责任公司1CXHL23004701CXHL23004711CXHL23004721CXHL2300473FT-004注射液方拓生物科技(苏州)有限公司1CXSL2300275GT201注射液苏州沙砾生物科技有限公司1CXSL2300290HB0025注射液华博生物医药技术(上海)有限公司1CXSL2300307HB0030注射液1CXSL2300308HZ012注射液浙江和泽医药科技股份有限公司1CXHL2300482IPG11406片南京艾美斐生物医药科技有限公司1CXHL23004751CXHL23004761CXHL23004771CXHL23004781CXHL23004791CXHL2300480ISM3091胶囊英矽智能科技(上海)有限公司1CXHL23004541CXHL2300455KEM2102凝胶贴膏长沙晶易医药科技股份有限公司2.2CXHL2300433LM103注射液苏州蓝马医疗技术有限公司1CXSL2300304QJ-19-0002片江苏正大清江制药有限公司1CXHL23004911CXHL23004921CXHL2300493VGM-R02b上海天泽云泰生物医药有限公司1CXSL2300294XZ21026四川奥邦古得药业有限公司2.2CXHL2300431二价肠道病毒灭活疫苗(Vero细胞)北京科兴生物制品有限公司1.4CXSL23002911.4CXSL23002921.4CXSL2300293抗人CD70 T细胞注射液上海恒润达生生物科技股份有限公司1CXSL2300271注射用9MW2921迈威(上海)生物科技股份有限公司1CXSL2300327注射用BLB101北京力邦生物医药科技有限公司3.3CXSL2300317注射用IBD0333盛禾(中国)生物制药有限公司1CXSL2300306注射用MCLA-129贝达药业股份有限公司1CXSL2300322注射用SHR-A2009苏州盛迪亚生物医药有限公司1CXSL2300321注射用TFX05-01深圳扬厉医药技术有限公司1CXHL2300504甲磺酸贝福替尼胶囊贝达药业股份有限公司1CXHL23004941CXHL2300495重组人5型腺病毒注射液上海三维生物技术有限公司2.2CXSL2300273阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2300324仿制药申请药品名称企业名称分类受理号伏格列波糖片浙江海翔药业股份有限公司4CYHS2102303依诺肝素钠注射液烟台东诚北方制药有限公司4CYHS22001504CYHS2200151利丙双卡因乳膏湖北人福成田药业有限公司4CYHS2102260利伐沙班片山东裕欣药业有限公司4CYHS2201346单硝酸异山梨酯珠海润都制药股份有限公司4CYHS2260143唑来膦酸注射液四川汇宇制药股份有限公司4CYHS2102058地氯雷他定口服溶液浙江普利药业有限公司3CYHS2301447贵州阜康仁制药有限公司3CYHS2200014安徽新世纪药业有限公司3CYHS2102216塞来昔布胶囊四川新斯顿制药股份有限公司4CYHS2200312头孢地尼胶囊深圳立健药业有限公司4CYHS2102182富马酸福莫特罗吸入溶液健康元药业集团股份有限公司3CYHS2102232对乙酰氨基酚注射液中国大冢制药有限公司3CYHS2201756对乙酰氨基酚甘露醇注射液吉林康乃尔药业有限公司3CYHS2300699普瑞巴林胶囊四川制药制剂有限公司4CYHS21020194CYHS2102020氢化可的松缓释片津药药业股份有限公司3CYHL23000673CYHL2300068泊沙康唑肠溶片齐鲁制药(海南)有限公司4CYHS2200251注射用特利加压素蓬莱诺康药业有限公司4CYHS2101896混合糖电解质注射液珠海经济特区生物化学制药厂6CYHS1300681盐酸普拉格雷片重庆医药(集团)股份有限公司3CYHS21016543CYHS2101653磷酸奥司他韦干混悬剂石家庄四药有限公司3CYHS2200020磷酸西格列汀片江苏万邦生化医药集团有限责任公司4CYHS21018534CYHS21018544CYHS2101855肠内营养混悬液(TP-MCT)北京华信通药业有限公司6CYHS1401028艾曲泊帕乙醇胺片远大医药(中国)有限公司4CYHS2201681宏越科技(湖州)有限公司4CYHS2201650苯磺顺阿曲库铵注射液南京斯泰尔医药科技有限公司4CYHS2102015醋酸西曲瑞克翰宇药业(武汉)有限公司4CYHS2260223钆布醇注射液湖南科伦制药有限公司4CYHS2101712阿哌沙班片上海理想制药有限公司4CYHS2101121马来酸阿法替尼片上海创诺制药有限公司4CYHS2101055进口申请药品名称企业名称分类受理号decitabine and cedazuridine 片Otsuka Pharmaceutical Co., Ltd2.2JXHL2300103Anifrolumab注射液AstraZeneca AB2.2JXSL2300092GSK3858279 注射液GlaxoSmithKline Trading Services Limited1JXSL23000771JXSL2300078LY3502970胶囊Eli Lilly and Company1JXHL23001041JXHL23001051JXHL23001061JXHL23001071JXHL23001081JXHL2300109STC314注射液Grand Medical Pty Ltd.1JXHL2300088TV-44749Teva Branded Pharmaceutical Products R&D, Inc.2.2JXHL2300099Vamorolone口服混悬液Santhera Pharmaceuticals (Switzerland) Ltd.1JXHL2300093VAY736注射液Novartis Pharma AG1JXSL2300091卡替拉韦注射液ViiV Healthcare BV5.1JXHS21010835.1JXHS2101084卡替拉韦钠片5.1JXHS2101085咪唑立宾片旭化成制药株式会社5.1JXHS20000805.1JXHS20000815.1JXHS20000825.1JXHS2000079氟维司群注射液AMNEAL PHARMACEUTICALS PVT. LTD.5.2JYHS2300005注射用NacubactamMeiji Seika Pharma Co., Ltd.1JXHL2300094注射用塞替派MSN Laboratories Private Limited5.2JYHS21010525.2JYHS2101051盐酸多奈哌齐片阿拉宾度制药有限公司5.2JXHS1900054碳酸镧咀嚼片InvaGen Pharmaceuticals, Inc5.2JYHS2200068萨特利珠单抗注射液F. Hoffmann-La Roche Ltd.2.2JXSL2300071中药相关申请药品名称企业名称分类受理号参蓉颗粒石家庄以岭药业股份有限公司1.1CXZL2300034小儿银连颗粒一力制药(罗定)有限公司1.1CXZL2300032神白散北京麦迪信医药科技发展有限公司3CXZS0700318注：灰色字体部分结论为不批准或收到通知件；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗申请上市

2022-11-20

·GBIHealth

罗氏、恒瑞等加入张江AI新药研发联盟；李氏大药厂最新财报；百悦泽欧洲获批用于CLL患者

药讯精选GBI NEWS百济神州百悦泽于欧洲获批用于CLL患者百济神州宣布，旗下布鲁顿氏酪氨酸激酶（BTK）抑制剂百悦泽（泽布替尼）已获欧盟委员会（EC）批准上市，用于治疗初治（TN）或复发/难治性（R/R）慢性淋巴细胞白血病（CLL）成人患者。本次批准基于两项III期临床试验的积极结果，分别为在既往未经治疗的CLL患者中开展的SEQUOIA试验（NCT03336333）和在R/R CLL患者中开展的ALPINE试验（NCT03734016）。两项试验表明，无论是与苯达莫司汀联合利妥昔单抗（B+R）相比用于一线CLL治疗，还是与伊布替尼相比用于R/R CLL治疗，百悦泽均呈现优效性。百悦泽是唯一经独立评审委员会（IRC）评估在R/R CLL中对比伊布替尼获得优效性的BTK抑制剂（总缓解率[ORR]：80.4%vs 72.9%）。且相较于伊布替尼，接受百悦泽治疗的患者中有更多在一年后仍维持缓解状态（78%vs90%）。百悦泽总体安全性特征良好，与既往报道一致。**关注GBISOURCE数据库公众号在线查看新闻详情海思科支气管扩张症新药HSK31858片II期临试获伦理批准海思科医药集团股份有限公司发布公告称，评估旗下HSK31858片在非囊性纤维化支气管扩张（NCFBE）患者中有效性和安全性的多中心、随机、双盲、安慰剂对照的Ⅱ期研究获得组长单位广州医科大学附属第一医院医学伦理委员会的伦理批准。HSK31858片是海思科自主研发的一种口服、强效和高选择性的二肽基肽酶1（DPP1）小分子抑制剂，临床拟用于治疗支气管扩张症及急性肺损伤/急性呼吸窘迫综合征引起的下呼吸道疾病。截至公告披露日，全球尚未有同靶点药物获批上市。此前HSK31858片已分别在澳洲和中国完成了I期临床试验。**关注GBISOURCE数据库公众号在线查看新闻详情企业动态GBI NEWS罗氏、恒瑞、锐格医药等近20家企业加入张江AI新药研发联盟锐格医药、罗氏、恒瑞、药明生物、联拓生物、百度、圆壹智慧、星药、宇道生物、英飞智药等企业加入张江AI新药研发联盟。张江AI新药研发联盟由陈凯先、蒋华良、饶子和三位院士倡议，近20家企业机构联合组建，旨在以关键项目为牵引、联合开展协同攻关，以本地生态为基底、共同提升本地生态密度。AI新药研发联盟将进一步推动跨学科技术融合、促成产业交流、加速新药研发，构建更有活力的张江智药产业生态。**关注GBISOURCE数据库公众号在线查看新闻详情李氏大药厂2022年前三季度财报：增收8.8%至10.36亿港元李氏大药厂发布截至2022年9月30日止九个月公司业绩。报告期内公司总收益为10.36亿港元，同比增长8.8%；主要得益于布累迪宁（咪唑立宾）、曲前列尼尔注射液、尤靖安（重组人干扰素α2b凝胶）贡献的销售额上涨，抵销了部分门诊药物以及外科药物的销售额跌幅。2022年第三季度内，公司收益为3.87亿港元，同比增长5.1%，环比增长19.3%。引进产品于2022年前九个月的销售额占集团收益的61.7%，专利产品及仿制产品占38.3%。研发费用合计2.94亿港元，较去年同期减少14.9%；销售及分销费用为2.69亿港元，同比增长4.0%。截至目前，李氏大药厂管线中有超过40个分别处于早期至后期开发阶段的项目。**关注GBISOURCE数据库公众号在线查看新闻详情2.66亿美元！Tenacia获得Marinus旗下ganaxolone大中华区独家权益美国制药公司Marinus Pharmaceuticals Inc.与中国公司Tenacia Biotechnology（Shanghai）Co.，Ltd.签署了合作和供应协议。Tenacia将获得在中国大陆、香港、澳门和台湾开发和商业化Marinus旗下ganaxolone口服和静脉注射制剂的独家权利。Tenacia还有权就未来任何一款新一代制剂或前药优先谈判。根据协议，Marinus将获得1000万美元的预付款，高达2.56亿美元的行政监管、开发和销售里程碑付款，以及基于未来净销售额的低两位数的分级特许权使用费。**关注GBISOURCE数据库公众号在线查看新闻详情器械要闻GBI NEWS百心安多电极肾动脉射频消融系统申报临床急需，有望落地乐城上海百心安生物技术股份有限公司发布公告称，旗下Iberis多电极肾动脉射频消融系统（RDN）已通过瑞金海南医院伦理委员会审批，即将向海南省药品监督管理局及海南省卫生健康委员会申请正式准入并用于临床急需。RDN技术可为无法通过高血压药物治疗有效控制血压的患者带来新的希望，并有望实现长久稳定且24小时不间断的血压控制，减少药物使用量，打破了患者只能依赖药物降压的困境。百心安RDN产品此前已于2016年获得CE认证在欧盟上市。依据相关政策，该产品有望于海南博鳌乐城国际医疗旅游先行区获批，惠及中国患者。**戳文末“阅读原文”定制/订阅新闻资讯江苏百优达创新器械人工血管获批上市根据国家药品监督管理局公示，江苏百优达生命科技有限公司生产的创新产品“人工血管”获批注册。人工血管主要由PET线编织制成，涂覆有牛胶原蛋白和甘油。该产品的聚酯编织采用创新编制工艺，使织物具有更小且更均匀的孔隙，预期将改进成品的渗血性能。人工血管用于主动脉及其分支血管的置换或旁路手术。该产品的上市将为临床治疗提供更多选择。**戳文末“阅读原文”定制/订阅新闻资讯重磅推荐《高值创新药医保报销风险管理——国际经验：创新型支付协议从概念到案例》报告由清华大学医院管理研究院教授兼研究员、GBI首席顾问陈怡博士撰写，报告在汇总相关国际文献基础上，梳理了创新型市场准入协议（Market Access Agreement, MAA）的发展背景、协议类别、实施条件、评估标准、案例和发展趋势，旨在帮助行业同仁系统地认识国际实践经验，并对未来如何建立适合我国的高值药品准入支付方式解决思路带来启示与思考。滑动查看报告目录扫描二维码或点击“阅读原文”解锁完整版报告精彩内容。点击阅读原文获取完整版报告

财报临床3期临床2期上市批准申请上市

2022-07-28

·医药魔方

全球首款！贝利尤单抗获FDA批准治疗儿童狼疮肾炎

7月27日，GSK宣布贝利尤单抗（Benlysta）新适应症获FDA批准，用于治疗正在接受标准治疗的5岁至17岁狼疮性肾炎（LN）患者。贝利尤单抗于2020年12月获FDA批准用于治疗LN成人患者，目前，又扩大适用人群至5岁及以上儿科LN患者，成为了全球首款且唯一一款治疗儿童LN的生物制剂。狼疮性肾炎是一种由系统性红斑狼疮（SLE）引起的严重肾脏炎症，患者症状表现为蛋白尿、血清肌酐升高和尿沉渣等。如果控制不佳，LN可能会进展为终末期肾脏病，甚至死亡。据统计，美国约有20万-30万例SLE患者，其中近1/3患者在确诊时已经进展至LN。在此之前，儿科LN患者的治疗选择主要局限于使用非选择性免疫抑制剂和皮质类固醇。贝利尤单抗是一种B淋巴细胞刺激因子（BLyS）特异性抑制剂，通过与BLyS结合，以阻断BLyS与B细胞上的受体结合，抑制B细胞的存活并减少B细胞向产生免疫球蛋白的浆细胞分化。它于2011年首次获批，是50多年来首个也是目前唯一一个同时被批准用于SLE和LN的生物制剂。目前，已上市的治疗LN成人患者的药物有4款，分别是伏环孢素、贝利尤单抗、吗替麦考酚酯、咪唑立宾。医药魔方NextPharma“活动性狼疮肾炎是狼疮儿童潜在的严重并发症，大多数病例发生在最初诊断狼疮后的头两年内，”美国狼疮基金会总裁兼首席执行官Stevan W. Gibson表示“这项批准标志着在为这些在生命早期有肾损伤风险的儿童提供治疗选择方面向前迈出了重要一步。”

免疫疗法抗体

100 项与咪唑立宾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01392	咪唑立宾	L04AX	DB12617

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾病综合征	日本	Asahi Kasei Corp.	1995-09-29
类风湿关节炎	日本	Asahi Kasei Corp.	1992-10-02
狼疮性肾炎	日本	Asahi Kasei Corp.	1990-09-28
肾移植排斥反应	日本	Asahi Kasei Corp.	1984-02-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
狼疮性肾炎	申请上市	中国	Asahi Kasei Corp.	2022-01-30
肾病综合征	申请上市	中国	Asahi Kasei Corp.	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2016	N/A	风湿性多肌痛	24	Mizoribine	鏇夢簾襯蓋積獵廠糧壓(構鏇艱壓網衊積繭餘餘) = 1 patient developed gastrointestinal symptom in MTX group, and 1 patient developed gastrointestinal symptom in MZR group 鏇齋繭鬱窪襯壓鏇餘糧 (繭繭憲夢蓋鹹積顧膚製 ) 更多	积极	2016-06-08
EULAR2016	N/A	风湿性多肌痛	24	Methotrexate		积极	2016-06-08
EULAR2008	N/A	干燥综合征	29	Mizoribine 150 mg/day	(鬱繭鏇範淵膚餘膚範憲) = 鬱網簾壓顧積獵網蓋觸顧夢製壓築獵廠製憲艱 (獵簾夢衊鹹壓鏇糧窪積, 57.0)	积极	2008-06-11
EULAR2010	N/A	胶原蛋白疾病 \| 类风湿关节炎	-	Mizoribine 100-150 mg/day	壓餘鬱廠壓鏇網廠艱糧(選齋鑰繭築餘繭願蓋糧) = no severe side effects developed 糧製窪淵觸獵製蓋顧選 (網遞齋廠艱夢願艱顧艱 ) 更多	积极	2010-06-16
NCT02373202 (CTgov)	临床3期	类风湿关节炎	91	Sarilumab+Mizoribine+Tacrolimus+Sulfasalazine+Leflunomide+Bucillamine (Sarilumab 150 mg q2w + DMARDs)	(選淵選願膚網顧鬱糧網) = 觸遞鏇廠廠餘選製壓夢淵糧廠構構餘願觸選齋 (獵鏇繭獵齋醖願夢範選, 艱積簾積鑰鏇鬱鑰艱淵 ~ 窪遞顧窪鹹觸顧廠淵齋) 更多	-	2018-01-30
NCT02373202 (CTgov)	临床3期	类风湿关节炎	91	Sarilumab+Mizoribine+Tacrolimus+Sulfasalazine+Leflunomide+Bucillamine (Sarilumab 200 mg q2w + DMARDs)	(選淵選願膚網顧鬱糧網) = 襯壓鏇壓鏇壓醖齋衊繭淵糧廠構構餘願觸選齋 (獵鏇繭獵齋醖願夢範選, 鬱築齋築選衊構憲鬱窪 ~ 範製艱襯窪網築膚鬱遞) 更多	-	2018-01-30
MILE 2010 (EULAR2015)	N/A	狼疮性肾炎	576	Mizoribine	(積糧夢鬱醖顧襯窪遞衊) = Adverse reactions occurred in 60 of the 443 subjects (13.5%). The main adverse reactions were 12 events (2.7%) of herpes zoster, 5 events (1.1%) of hyperuricemia, and 4 events (0.9%) of anemia. Serious adverse drug reactions were observed in 12 patients (2.7%) 願廠夢範鑰簾觸選淵範 (醖製獵壓鏇簾鹽選壓醖 )	积极	2015-06-10